{"title":"可溶性程序性死亡配体-1（sPD-L1）对癌症预后价值的荟萃分析。","authors":"Jinfan Sun, Shuenqin Hu, Xiuying Li","doi":"10.1080/1354750X.2023.2198168","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The soluble programmed death ligand-1 (sPD-L1) and its prognostic role in cancers have been investigated in numerous studies. However, due to the inconsistency on some findings, this meta-analysis was performed to assess the prognostic value of sPD-L1 in patients with cancer.</p><p><strong>Methods: </strong>We searched the PubMed, Web of Science, MEDLINE, Wiley Online Library and ScienceDirect, and screened the studies for eligibility. Recurrence-free survival (RFS), progression-free survival (PFS) and disease-free survival (DFS) were for short term survival. The overall survival (OS) was for long term survival.</p><p><strong>Results: </strong>Forty studies with 4441 patients were included in this meta-analysis. Elevated sPD-L1 was associated with short OS [HR = 2.44 (2.03-2.94), <i>p</i> = 0.000]. Moreover, a high sPD-L1 was predictive of worse DFS/RFS/PFS [HR = 2.52 (1.83-3.44), <i>p</i> = 0.000]. In addition, high sPD-L1 was consistently correlated with poor OS in irrespective of study type, univariate and multivariate analysis, ethnicity, cut-off value of sPD-L1, sample and treatment. In the subgroup analysis, high sPD-L1 was correlated with poor OS in gastrointestinal cancer, lung cancer, hepatic cancer, oesophageal cancer and clear cell renal cell carcinoma.</p><p><strong>Conclusions: </strong>The present meta-analysis showed that a high level of sPD-L1 was associated with worse prognosis in some types of cancer.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"477-485"},"PeriodicalIF":2.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.\",\"authors\":\"Jinfan Sun, Shuenqin Hu, Xiuying Li\",\"doi\":\"10.1080/1354750X.2023.2198168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The soluble programmed death ligand-1 (sPD-L1) and its prognostic role in cancers have been investigated in numerous studies. However, due to the inconsistency on some findings, this meta-analysis was performed to assess the prognostic value of sPD-L1 in patients with cancer.</p><p><strong>Methods: </strong>We searched the PubMed, Web of Science, MEDLINE, Wiley Online Library and ScienceDirect, and screened the studies for eligibility. Recurrence-free survival (RFS), progression-free survival (PFS) and disease-free survival (DFS) were for short term survival. The overall survival (OS) was for long term survival.</p><p><strong>Results: </strong>Forty studies with 4441 patients were included in this meta-analysis. Elevated sPD-L1 was associated with short OS [HR = 2.44 (2.03-2.94), <i>p</i> = 0.000]. Moreover, a high sPD-L1 was predictive of worse DFS/RFS/PFS [HR = 2.52 (1.83-3.44), <i>p</i> = 0.000]. In addition, high sPD-L1 was consistently correlated with poor OS in irrespective of study type, univariate and multivariate analysis, ethnicity, cut-off value of sPD-L1, sample and treatment. In the subgroup analysis, high sPD-L1 was correlated with poor OS in gastrointestinal cancer, lung cancer, hepatic cancer, oesophageal cancer and clear cell renal cell carcinoma.</p><p><strong>Conclusions: </strong>The present meta-analysis showed that a high level of sPD-L1 was associated with worse prognosis in some types of cancer.</p>\",\"PeriodicalId\":8921,\"journal\":{\"name\":\"Biomarkers\",\"volume\":\" \",\"pages\":\"477-485\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1354750X.2023.2198168\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2023.2198168","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：可溶性程序性死亡配体-1（sPD-L1）及其在癌症中的预后作用已在许多研究中得到研究。然而，由于一些研究结果的不一致性，本荟萃分析旨在评估sPD-L1在癌症患者中的预后价值。方法：我们搜索PubMed、Web of Science、MEDLINE、Wiley Online Library和ScienceDirect，并对研究进行资格筛选。无复发生存期（RFS）、无进展生存期（PFS）和无病生存期（DFS）为短期生存期。总生存率（OS）为长期生存率。结果：本荟萃分析纳入了40项研究，共4441名患者。sPD-L1升高与OS短相关[HR=2.44（2.03-2.94），p = 0.000]。此外，高sPD-L1可预测更差的DFS/RFS/PFS[HR=2.52（1.83-3.44），p = 0.000]。此外，无论研究类型、单变量和多变量分析、种族、sPD-L1的临界值、样本和治疗如何，高sPD-L1与低OS始终相关。在亚组分析中，高sPD-L1与胃肠道癌症、癌症、癌症、癌症食管癌和肾透明细胞癌的OS低相关。结论：目前的荟萃分析表明，在某些类型的癌症中，高水平的sPD-L1与更差的预后相关。
Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.
Background: The soluble programmed death ligand-1 (sPD-L1) and its prognostic role in cancers have been investigated in numerous studies. However, due to the inconsistency on some findings, this meta-analysis was performed to assess the prognostic value of sPD-L1 in patients with cancer.
Methods: We searched the PubMed, Web of Science, MEDLINE, Wiley Online Library and ScienceDirect, and screened the studies for eligibility. Recurrence-free survival (RFS), progression-free survival (PFS) and disease-free survival (DFS) were for short term survival. The overall survival (OS) was for long term survival.
Results: Forty studies with 4441 patients were included in this meta-analysis. Elevated sPD-L1 was associated with short OS [HR = 2.44 (2.03-2.94), p = 0.000]. Moreover, a high sPD-L1 was predictive of worse DFS/RFS/PFS [HR = 2.52 (1.83-3.44), p = 0.000]. In addition, high sPD-L1 was consistently correlated with poor OS in irrespective of study type, univariate and multivariate analysis, ethnicity, cut-off value of sPD-L1, sample and treatment. In the subgroup analysis, high sPD-L1 was correlated with poor OS in gastrointestinal cancer, lung cancer, hepatic cancer, oesophageal cancer and clear cell renal cell carcinoma.
Conclusions: The present meta-analysis showed that a high level of sPD-L1 was associated with worse prognosis in some types of cancer.
期刊介绍：
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
